24/7 Market News Snapshot 20 October, 2025 – Verrica Pharmaceuticals Inc. Common Stock (NASDAQ:VRCA)

DENVER, Colo., 20 October, 2025 (www.247marketnews.com) – (NASDAQ:VRCA) are discussed in this article.
Verrica Pharmaceuticals Inc. is making significant strides within the biotechnology sector, showcasing both an impressive surge in stock value and advancing critical regulatory steps for its innovative treatments. The company’s stock opened at $4.17 and experienced a remarkable increase, trading at $5.134, reflecting a notable gain of 23.71% after closing at $4.15. This surge, driven by robust trading activity with over 1.28 million shares exchanged, indicates a burgeoning investor interest, positioning Verrica as a stock to watch within the market.

In a pivotal development, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has determined that the existing clinical data from Verrica’s Phase 3 trials in the U.S. and Japan is sufficient to support a Marketing Authorization Application (MAA) for its groundbreaking product, YCANTH®. This treatment offers a new solution for molluscum contagiosum, a contagious skin disease affecting millions.

The CHMP’s endorsement negates the need for additional Phase 3 studies, allowing the company to commence preparations for a filing slated for late 2026. Jayson Rieger, PhD, MBA, the President and CEO of Verrica, expressed enthusiasm for this regulatory alignment, emphasizing the significant unmet needs in the European market for patients suffering from molluscum.

YCANTH® is a proprietary drug-device combination that employs a GMP-controlled formulation of cantharidin, delivered via an easy-to-use applicator. It is already approved in the U.S. for patients ages two and older, marking it as the first therapeutic specifically targeting molluscum. As Verrica progresses towards its European approval, the company remains dedicated to enhancing patient care through innovative solutions in dermatology, affirming its commitment to addressing urgent medical needs in skin diseases.

Related news for (VRCA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.